-
World Health Organization, 2012a: Outbreak news. Ebola, Democratic Republic of the Congo[J]. Wkly Epidemiol Rec, 87, 421-.
-
World Health Organization, 2012b: Outbreak news. Marburg haemorrhagic fever, Uganda[J]. Wkly Epidemiol Rec, 87, 414-.
-
Basler C F, Amarasinghe G K, 2009: Evasion of interferon responses by Ebola and Marburg viruses[J]. J Interferon Cytokine Res, 29, 511-520. doi: 10.1089/jir.2009.0076
-
Bavari S, Bosio C M, Wiegand E, Ruthel G, Will A B, Geisbert T W, Hevey M, Schmaljohn C, Schmaljohn A, Aman M J, 2002: Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses[J]. J Exp Med, 195, 593-602. doi: 10.1084/jem.20011500
-
Bosio C M, Moore B D, Warfield K L, Ruthel G, Mohamadzadeh M, Aman M J, Bavari S, 2004: Ebola and Marburg virus-like particles activate human myeloid dendritic cells[J]. Virology, 326, 280-287. doi: 10.1016/j.virol.2004.05.025
-
Bosio C M, Aman M J, Grogan C, Hogan R, Ruthel G, Negley D, Mohamadzadeh M, Bavari S, Schmaljohn A, 2003: Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation[J]. J Infect Dis, 188, 1630-1638. doi: 10.1086/jid.2003.188.issue-11
-
Bradfute S B, Dye J M, J r., and Bavari S, 2011: Filovirus vaccines[J]. Hum Vaccin, 7, 701-711. doi: 10.4161/hv.7.6.15398
-
Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J, 1998: A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever[J]. J Infect Dis, 178, 651-661. doi: 10.1086/jid.1998.178.issue-3
-
Cardenas W B, Loo Y M, Gale M, J r., Hartman A L, Kimberlin C R, Martinez-Sobrido L, Saphire E O, Basler C F, 2006: Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling[J]. J Virol, 80, 5168-5178. doi: 10.1128/JVI.02199-05
-
Chang T H, Kubota T, Matsuoka M, Jones S, Bradfute S B, Bray M, Ozato K, 2009: Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery[J]. PLoS Pathog, 5, e1000493-. doi: 10.1371/journal.ppat.1000493
-
Feldmann H, Klenk H D, Sanchez A, 1993: Molecular biology and evolution of filoviruses[J]. Arch Virol Suppl, 7, 81-100. doi: 10.1007/978-3-7091-9300-6
-
Johnson R F, Bell P, Harty R N, 2006: Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology[J]. Virol J, 3, 31-. doi: 10.1186/1743-422X-3-31
-
Leung L W, Park M S, Martinez O, Valmas C, Lopez C B, Basler C F, 2011: Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells[J]. Immunol Cell Biol, 89, 792-802. doi: 10.1038/icb.2010.169
-
Licata J M, Johnson R F, Han Z, Harty R N, 2004: Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles[J]. J Virol, 78, 7344-7351. doi: 10.1128/JVI.78.14.7344-7351.2004
-
Makino A, Yamayoshi S, Shinya K, Noda T, Kawaoka Y, 2011: Identification of amino acids in Marburg virus VP40 that are important for virus-like particle budding[J]. J Infect Dis, 204, S871-877.
-
Martinez O, Valmas C, Basler C F, 2007: Ebola virus-like particle-induced activation of NF-kappaB and Erk signaling in human dendritic cells requires the glycoprotein mucin domain[J]. Virology, 364, 342-354. doi: 10.1016/j.virol.2007.03.020
-
Okumura A, Pitha P M, Harty R N, 2008: ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity[J]. Proc Natl Acad Sci U S A, 105, 3974-3979. doi: 10.1073/pnas.0710629105
-
Sullivan N J, Martin J E, Graham B S, Nabel G J, 2009: Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule[J]. Nat Rev Microbiol, 7, 393-400. doi: 10.1038/nrmicro2129
-
Swenson D L, Warfield K L, Negley D L, Schmaljohn A, Aman M J, Bavari S, 2005: Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections[J]. Vaccine, 23, 3033-3042. doi: 10.1016/j.vaccine.2004.11.070
-
Swenson D L, Warfield K L, Kuehl K, Larsen T, Hevey M C, Schmaljohn A, Bavari S, Aman M J, 2004: Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein[J]. FEMS Immunol Med Microbiol, 40, 27-31. doi: 10.1016/S0928-8244(03)00273-6
-
Swenson D L, Wang D, Luo M, Warfield K L, Woraratanadharm J, Holman D H, Dong J Y, Pratt W D, 2008: Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections[J]. Clin Vaccine Immunol, 15, 460-467. doi: 10.1128/CVI.00431-07
-
Wahl-Jensen V, Kurz S K, Hazelton P R, Schnittler H J, Stroher U, Burton D R, Feldmann H, 2005: Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages[J]. J Virol, 79, 2413-2419. doi: 10.1128/JVI.79.4.2413-2419.2005
-
Wahl-Jensen V, Kurz S, Feldmann F, Buehler L K, Kindrachuk J, DeFilippis V, da Silva Correia J, Fruh K, Kuhn J H, Burton D R, Feldmann H, 2011: Ebola virion attachment and entry into human macrophages profoundly effects early cellular gene expression[J]. PLoS Negl Trop Dis, 5, e1359-. doi: 10.1371/journal.pntd.0001359
-
Wahl-Jensen V M, Afanasieva T A, Seebach J, Stroher U, Feldmann H, Schnittler H J, 2005: Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function[J]. J Virol, 79, 10442-10450. doi: 10.1128/JVI.79.16.10442-10450.2005
-
Warfield K L, Deal E M, Bavari S, 2009: Filovirus infections[J]. J Am Vet Med Assoc, 234, 1130-1139. doi: 10.2460/javma.234.9.1130
-
Warfield K L, Swenson D L, Negley D L, Schmaljohn A L, Aman M J, Bavari S, 2004: Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection[J]. Vaccine, 22, 3495-3502. doi: 10.1016/j.vaccine.2004.01.063
-
Warfield K L, Swenson D L, Olinger G G, Kalina W V, Aman M J, Bavari S, 2007: Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge[J]. J Infect Dis, 196, S430-437.
-
Warfield K L, Bosio C M, Welcher B C, Deal E M, Mohamadzadeh M, Schmaljohn A, Aman M J, Bavari S, 2003: Ebola virus-like particles protect from lethal Ebola virus infection[J]. Proc Natl Acad Sci U S A, 100, 15889-15894. doi: 10.1073/pnas.2237038100
-
Warfield K L, Olinger G, Deal E M, Swenson D L, Bailey M, Negley D L, Hart M K, Bavari S, 2005: Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection[J]. J Immunol, 175, 1184-1191. doi: 10.4049/jimmunol.175.2.1184
-
Warfield K L, Perkins J G, Swenson D L, Deal E M, Bosio C M, Aman M J, Yokoyama W M, Young H A, Bavari S, 2004: Role of natural killer cells in innate protection against lethal ebola virus infection[J]. J Exp Med, 200, 169-179. doi: 10.1084/jem.20032141
-
Warfield K L, Posten N A, Swenson D L, Olinger G G, Esposito D, Gillette W K, Hopkins R F, Costantino J, Panchal R G, Hartley J L, Aman M J, Bavari S, 2007: Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents[J]. J Infect Dis, 196, S421-429.
-
Yasuda J, Nakao M, Kawaoka Y, Shida H, 2003: Nedd4 regulates egress of Ebola virus-like particles from host cells[J]. J Virol, 77, 9987-9992. doi: 10.1128/JVI.77.18.9987-9992.2003